公开(公告)号：US20170258908A1

公开(公告)日：2017-09-14

申请号：US15600921

申请日：2017-05-22

Applicant: IMMUNOLIGHT, LLC

Inventor： Frederic A. BOURKE, JR.

IPC: A61K41/00 ,  A61F7/00 ,  A61H23/00 ,  A61K31/35 ,  A61K31/366 ,  A61K31/37 ,  A61K31/714 ,  A61K45/06 ,  A61K47/02 ,  A61N2/02 ,  A61N5/06 ,  A61N5/10

CPC classification number: A61K41/0071 ,  A61F7/00 ,  A61H23/00 ,  A61K31/35 ,  A61K31/366 ,  A61K31/37 ,  A61K31/714 ,  A61K41/00 ,  A61K41/0066 ,  A61K41/008 ,  A61K45/06 ,  A61K47/02 ,  A61N2/02 ,  A61N5/062 ,  A61N5/10 ,  A61N2005/0656 ,  A61N2005/1089 ,  A61N2005/1098 ,  A61K2300/00

Abstract: Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US20170196977A1

公开(公告)日：2017-07-13

申请号：US15469114

申请日：2017-03-24

Applicant: DUKE UNIVERSITY ,  IMMUNOLIGHT, LLC

Inventor： Tuan VO-DINH ,  Frederic A. Bourke, JR.

IPC: A61K41/00 ,  A61N5/06 ,  A61K39/00 ,  A61K31/37

CPC classification number: A61K41/0061 ,  A61K9/14 ,  A61K9/143 ,  A61K31/37 ,  A61K39/00 ,  A61K41/0028 ,  A61K41/0066 ,  A61K47/52 ,  A61K2039/57 ,  A61N5/06 ,  A61N5/062

Abstract: The use of plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, the PEPST and EPEP agents and probes used therein, and pharmaceutical compositions using and/or containing the same.

公开(公告)号：US09662388B2

公开(公告)日：2017-05-30

申请号：US14947255

申请日：2015-11-20

Applicant: Duke University ,  Immunolight, LLC

Inventor： Tuan Vo-Dinh ,  Frederic A. Bourke, Jr.

IPC: A61K41/00 ,  A61K39/00 ,  A61K31/37 ,  A61N5/06 ,  A61K9/14 ,  A61K47/48

CPC classification number: A61K41/0061 ,  A61K9/14 ,  A61K9/143 ,  A61K31/37 ,  A61K39/00 ,  A61K41/0028 ,  A61K41/0066 ,  A61K47/52 ,  A61K2039/57 ,  A61N5/06 ,  A61N5/062

Abstract: The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.

公开(公告)号：US20170121472A1

公开(公告)日：2017-05-04

申请号：US15408003

申请日：2017-01-17

Applicant: IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

Inventor： Frederic Avery BOURKE, JR. ,  Tuan Vo-Dinh

IPC: C08J3/28 ,  B01J23/52 ,  B01J23/50 ,  B01J31/02 ,  B01J31/22 ,  B01J37/00 ,  B01J37/02 ,  A61L2/10 ,  A61L2/08 ,  A61L2/00 ,  B01J19/12 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  B01J35/00

CPC classification number: B01J19/123 ,  A23L2/50 ,  A23L3/26 ,  A23L3/263 ,  A23L3/28 ,  A23L5/32 ,  A23V2002/00 ,  A61K41/0057 ,  A61K41/0066 ,  A61L2/0011 ,  A61L2/0047 ,  A61L2/0076 ,  A61L2/082 ,  A61L2/088 ,  A61L2/10 ,  A61L2/16 ,  A61L2202/21 ,  A61L2202/22 ,  A61M1/3683 ,  A61N5/062 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1087 ,  A61N2005/1089 ,  A61N2005/1098 ,  B01J19/082 ,  B01J19/085 ,  B01J19/12 ,  B01J19/125 ,  B01J19/127 ,  B01J19/128 ,  B01J23/50 ,  B01J23/52 ,  B01J31/0275 ,  B01J31/2295 ,  B01J35/0006 ,  B01J35/0013 ,  B01J35/004 ,  B01J37/0072 ,  B01J37/0221 ,  B01J2219/0877 ,  B01J2219/0879 ,  B01J2219/0892 ,  B01J2219/1203 ,  B01J2231/005 ,  B01J2531/005 ,  B01J2531/008 ,  B82Y20/00 ,  B82Y30/00 ,  B82Y40/00 ,  C02F1/30 ,  C02F1/302 ,  C02F1/305 ,  C02F1/307 ,  C02F1/32 ,  C02F1/725 ,  C02F2305/10 ,  C08J3/24 ,  C08J3/28 ,  C08J7/18 ,  C08J2300/00 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  C09J2205/31 ,  C12H1/06 ,  G02B5/008 ,  G21K5/00 ,  Y02W10/37 ,  Y10S977/774 ,  Y10S977/777 ,  Y10S977/896 ,  Y10S977/915 ,  Y10T156/10

Abstract: A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

公开(公告)号：US09622911B2

公开(公告)日：2017-04-18

申请号：US14206847

申请日：2014-03-12

Applicant: CXL Ophthalmics, LLC ,  Brad Hartman

Inventor： Roy S. Rubinfeld ,  Sandy T. Feldman ,  Kevin E. Daly ,  Raymond A. Hartman

IPC: A61B18/20 ,  A61F9/007 ,  A61N5/06 ,  A61K38/44 ,  A61K49/00 ,  A61F9/013 ,  A61F9/008

CPC classification number: A61F9/0079 ,  A61F9/008 ,  A61F9/013 ,  A61F2009/00865 ,  A61F2009/00872 ,  A61F2009/00893 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/525 ,  A61K38/44 ,  A61K41/0066 ,  A61K49/0015 ,  A61N5/062 ,  A61N2005/0626 ,  A61N2005/0652 ,  A61N2005/0661 ,  A61N2005/0663 ,  A61N2005/0667 ,  A61N2005/067 ,  A61K2300/00

Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

公开(公告)号：US09561292B1

公开(公告)日：2017-02-07

申请号：US13971822

申请日：2013-08-20

Applicant: Duke University

Inventor： Tuan Vo-Dinh ,  Hsiangkuo Yuan ,  Andrew Fales ,  Christopher Khoury

IPC: A61K9/14 ,  A61K49/00 ,  A61K41/00

CPC classification number: A61K41/0057 ,  A61K41/0052 ,  A61K41/0066 ,  A61K41/0071 ,  A61K49/1821 ,  G01N33/582

Abstract: A polymer-free synthesis method is provided for preparation of monodisperse nanostars. The nanostars can be used for treating and imaging cells in in vivo or ex vivo. The modes of treatment include use of a nanostar modified with a photo-activatable drug, which drug is activated by the photo-response of the nanostar to electromagnetic stimulation; use of a nanostar modified with a thermally-activatable drug, which drug is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which can directly or indirectly cause the death of an undesirable cell.

Abstract translation: 提供了一种无分子合成方法，用于制备单分散纳米颗粒。 纳米体系可用于体内或离体处理和成像细胞。 治疗方式包括使用用可光致活化药物修饰的纳米骨，该药物被纳米级的光响应激活以进行电磁刺激; 使用用可热激活的药物修饰的纳米级，该药物通过纳米级的热响应被激活以进行电磁刺激; 以及纳米星本身对电磁刺激的热响应，其可以直接或间接地导致不期望的细胞的死亡。

公开(公告)号：US20160354467A1

公开(公告)日：2016-12-08

申请号：US15226567

申请日：2016-08-02

Applicant: IMMUNOLIGHT, LLC.

Inventor： Frederic A. BOURKE, JR.

IPC: A61K41/00 ,  A61N5/06 ,  A61N5/10

CPC classification number: A61N5/10 ,  A23L2/50 ,  A23L3/26 ,  A23L3/263 ,  A23L3/28 ,  A23L5/32 ,  A23V2002/00 ,  A61K41/0057 ,  A61K41/0066 ,  A61L2/0011 ,  A61L2/0047 ,  A61L2/0076 ,  A61L2/082 ,  A61L2/088 ,  A61L2/10 ,  A61L2/16 ,  A61L2202/21 ,  A61L2202/22 ,  A61M1/3683 ,  A61N5/062 ,  A61N5/0624 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1087 ,  A61N2005/1089 ,  A61N2005/1098 ,  B01J19/082 ,  B01J19/085 ,  B01J19/12 ,  B01J19/123 ,  B01J19/125 ,  B01J19/127 ,  B01J19/128 ,  B01J23/50 ,  B01J23/52 ,  B01J31/0275 ,  B01J31/2295 ,  B01J35/0006 ,  B01J35/0013 ,  B01J35/004 ,  B01J37/0072 ,  B01J37/0221 ,  B01J2219/0877 ,  B01J2219/0879 ,  B01J2219/0892 ,  B01J2219/1203 ,  B01J2231/005 ,  B01J2531/005 ,  B01J2531/008 ,  B82Y20/00 ,  B82Y30/00 ,  B82Y40/00 ,  C02F1/30 ,  C02F1/302 ,  C02F1/305 ,  C02F1/307 ,  C02F1/32 ,  C02F1/725 ,  C02F2305/10 ,  C08J3/24 ,  C08J3/28 ,  C08J7/18 ,  C08J2300/00 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  C09J2205/31 ,  C12H1/06 ,  G02B5/008 ,  G21K5/00 ,  Y02W10/37 ,  Y10S977/774 ,  Y10S977/777 ,  Y10S977/896 ,  Y10S977/915 ,  Y10T156/10

Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

公开(公告)号：US09498643B2

公开(公告)日：2016-11-22

申请号：US14932435

申请日：2015-11-04

Applicant: IMMUNOLIGHT, LLC.

Inventor： Frederic A. Bourke, Jr.

IPC: A61N5/10 ,  A23L3/26 ,  C08J3/28 ,  C02F1/30 ,  B01J19/08 ,  A61L2/00 ,  B01J19/12 ,  C02F1/72 ,  A61L2/08 ,  A61L2/10 ,  A61L2/16 ,  G21K5/00 ,  A23L1/025 ,  C02F1/32 ,  A61K41/00 ,  A61N5/06 ,  B82Y20/00

CPC classification number: A61N5/10 ,  A23L2/50 ,  A23L3/26 ,  A23L3/263 ,  A23L3/28 ,  A23L5/32 ,  A23V2002/00 ,  A61K41/0057 ,  A61K41/0066 ,  A61L2/0011 ,  A61L2/0047 ,  A61L2/0076 ,  A61L2/082 ,  A61L2/088 ,  A61L2/10 ,  A61L2/16 ,  A61L2202/21 ,  A61L2202/22 ,  A61M1/3683 ,  A61N5/062 ,  A61N5/0624 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1087 ,  A61N2005/1089 ,  A61N2005/1098 ,  B01J19/082 ,  B01J19/085 ,  B01J19/12 ,  B01J19/123 ,  B01J19/125 ,  B01J19/127 ,  B01J19/128 ,  B01J23/50 ,  B01J23/52 ,  B01J31/0275 ,  B01J31/2295 ,  B01J35/0006 ,  B01J35/0013 ,  B01J35/004 ,  B01J37/0072 ,  B01J37/0221 ,  B01J2219/0877 ,  B01J2219/0879 ,  B01J2219/0892 ,  B01J2219/1203 ,  B01J2231/005 ,  B01J2531/005 ,  B01J2531/008 ,  B82Y20/00 ,  B82Y30/00 ,  B82Y40/00 ,  C02F1/30 ,  C02F1/302 ,  C02F1/305 ,  C02F1/307 ,  C02F1/32 ,  C02F1/725 ,  C02F2305/10 ,  C08J3/24 ,  C08J3/28 ,  C08J7/18 ,  C08J2300/00 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  C09J2205/31 ,  C12H1/06 ,  G02B5/008 ,  G21K5/00 ,  Y02W10/37 ,  Y10S977/774 ,  Y10S977/777 ,  Y10S977/896 ,  Y10S977/915 ,  Y10T156/10

Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

公开(公告)号：US20160331731A1

公开(公告)日：2016-11-17

申请号：US15220596

申请日：2016-07-27

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Wenle XIA ,  David Gooden ,  Erik J. Soderblom ,  Eric J. Toone ,  Neil L. Spector ,  Wayne F. Beyer, JR. ,  Harold Walder

IPC: A61K31/436 ,  A61K31/4709 ,  A61K41/00 ,  A61K45/06

CPC classification number: A61K31/436 ,  A61K31/37 ,  A61K31/4709 ,  A61K31/517 ,  A61K41/0066 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

公开(公告)号：US09439897B2

公开(公告)日：2016-09-13

申请号：US14603539

申请日：2015-01-23

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Wenle Xia ,  David Gooden ,  Erik J. Soderblom ,  Eric J. Toone ,  Neil L. Spector ,  Wayne F. Beyer, Jr. ,  Harold Walder

IPC: A61K31/517 ,  A61K31/4709 ,  A61K31/436 ,  A61K31/37 ,  A61K41/00

CPC classification number: A61K31/436 ,  A61K31/37 ,  A61K31/4709 ,  A61K31/517 ,  A61K41/0066 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

Abstract translation: 用于治疗受试者细胞增殖疾病或病症的方法，包括将缺乏DNA交联基序的补骨脂素衍生物施用于癌细胞，施用补骨脂素或其衍生物和拉帕替尼，或施用补骨脂素或其衍生物和神经胶质细胞 ，并且进一步施加起始辐射能量形成能量源。